By Chris Wack
ALX Oncology Holdings Inc. said it has entered into a clinical trial collaboration and supply agreement with Eli Lilly & Co. to evaluate the combination of ALX148, a next-generation CD47 blocker, and Cyramza ramucirumab, Lilly's anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer.
Under the terms of the agreement, ALX Oncology will conduct a randomized Phase 2/3 study to evaluate the efficacy of ALX148 in combination with ramucirumab, trastuzumab, and paclitaxel for the treatment of patients whose tumors have progressed following treatment with HER2-targeted therapy and chemotherapy. Lilly will supply ramucirumab for this trial.
Financial details of the collaboration agreement are undisclosed.
ALX Oncology owns worldwide commercial rights to ALX148.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires